`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`In the Inter Partes Review (IPR) of
`
`U.S. Patent Nos. 6,858,650, 7,384,980, 7,855,230, 7,985,772, and 8,338,478
`
`DECLARATION OF DEFOREST MCDUFF, Ph.D.
`
`I, DeForest McDuff, Ph.D., declare as follows:
`
`
`
`I.
`
`Introduction
`
` Qualifications
`
`1.
`
`I am a Vice President of Intensity Corporation and an expert in
`
`applied business economics, with more than ten years of experience in consulting,
`
`finance, and economic research. I provide expert witness testimony and consulting
`
`in a variety of areas, including lost profits, reasonable royalties, unjust enrichment,
`
`commercial success, finance, statistics, valuation, and business optimization.
`
`2. My expertise and experience span a variety of topics, including
`
`intellectual property, competition, antitrust, finance, labor, employment, and class
`
`action. My work in intellectual property spans the life sciences (including
`
`pharmaceuticals, biotechnology, diagnostics, and medical devices), electronics
`
`Declaration of DeForest McDuff, Ph.D.
`
`
`
`
`
`
`
`
`In the Inter Partes Review of U.S.
`Patent Nos. 6,858,650, 7,384,980,
`7,855,230, 7,985,772, 8,338,478
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1033 - Page 1
`
`
`
`(including consumer electronics, semiconductors, computers, and
`
`telecommunications), and has included projects on a diverse range of other
`
`industries (such as scuba diving equipment, golf clubs, and contact lenses). I
`
`frequently provide expertise and analysis in evaluating commercial success in the
`
`pharmaceutical industry.
`
`3.
`
`I earned my Ph.D. in economics from Princeton University. At
`
`Princeton, I received a National Science Foundation Graduate Research Fellowship
`
`for academic research studying economic and statistical properties of housing
`
`markets and financial derivatives. I have published research in several peer-
`
`reviewed academic journals. I graduated summa cum laude with undergraduate
`
`degrees in economics and mathematics from the University of Maryland.
`
`4. My curriculum vitae, provided in Exhibit 1034, contains more details
`
`on my background, experience, publications, and prior expert testimony.
`
`
`
`Scope of work
`
`5.
`
`Intensity Corporation has been retained by Kilpatrick Townsend &
`
`Stockton LLP on behalf of Mylan Pharmaceuticals Inc. (“Mylan”) in connection
`
`with my work in this matter. Intensity Corporation is being compensated at a rate
`
`of $725 per hour for my work and at lower rates for time spent by others on my
`
`team. The compensation of Intensity Corporation is not dependent on the
`
`substance of my testimony or the outcome of this matter.
`
`Declaration of DeForest McDuff, Ph.D.
`
`
`
`
`
`
`
`
`In the Inter Partes Review of U.S.
`Patent Nos. 6,858,650, 7,384,980,
`7,855,230, 7,985,772, 8,338,478
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1033 - Page 2
`
`
`
`6.
`
`For this declaration, I was asked to evaluate aspects of commercial
`
`success, from an economic perspective, as it pertains to Toviaz (fesoterodine) and
`
`U.S. Patent Nos. 6,858,650, 7,384,980, 7,855,230, 7,985,772, and 8,338,478
`
`(collectively, “the patents at issue”). This declaration is a statement of my
`
`opinions in this matter and the basis and reasons for those opinions. In forming the
`
`opinions expressed in this declaration, I have relied upon my education,
`
`experience, and knowledge of the subjects discussed. In connection with my work
`
`in this matter, I interviewed Steven E. Patterson, Ph.D., Professor and Associate
`
`Director at the Center for Drug Design, University of Minnesota, on January 22,
`
`2016, including discussion of: (1) the patents at issue, and (2) similarities and
`
`differences between Toviaz and Detrol/Detrol LA (tolterodine). I have also
`
`reviewed and relied upon documents and other materials that are cited herein.
`
`7.
`
`This declaration summarizes only my current opinions, which are
`
`subject to change depending upon additional information and/or analysis. I and
`
`others working under my direction prepared the exhibits as summaries of the
`
`information I reviewed and relied upon. The entirety of my declaration, including
`
`exhibits and referenced materials, supplies the basis for my analysis and
`
`conclusions. The organizational structure of the declaration is for convenience.
`
`To the extent that facts, economic analysis, and other considerations overlap, I
`
`generally discuss such issues only once for the sake of brevity. Neither the specific
`
`Declaration of DeForest McDuff, Ph.D.
`
`
`
`
`
`
`
`
`In the Inter Partes Review of U.S.
`Patent Nos. 6,858,650, 7,384,980,
`7,855,230, 7,985,772, 8,338,478
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1033 - Page 3
`
`
`
`order in which each issue is addressed nor the organization of my declaration or
`
`exhibits affects the ultimate outcome of my analysis.
`
`II. Background
`
` Overactive bladder
`
`8.
`
`Overactive bladder (“OAB”) is a condition primarily characterized by
`
`the sudden urge to urinate.1 Additional symptoms of OAB include a high
`
`frequency of urination throughout the day, awakening multiple times to urinate at
`
`night, and urge incontinence, the involuntary loss of urine following an urgent
`
`need to urinate.2 According to the Urology Care Foundation, approximately 33
`
`
`1 Mayo Clinic Website, Overactive Bladder, Definition,
`
`http://www.mayoclinic.org/diseases-conditions/overactive-
`
`bladder/basics/definition/con-20027632 (accessed 1/15/2016).
`
`
`
`Urology Care Foundation Website, What Is Overactive Bladder (OAB)?,
`
`http://www.urologyhealth.org/urologic-conditions/overactive-bladder-
`
`%28oab%29 (accessed 1/15/2016).
`
`2 Mayo Clinic Website, Overactive Bladder, Symptoms,
`
`http://www.mayoclinic.org/diseases-conditions/overactive-
`
`bladder/basics/symptoms/con-20027632 (accessed 1/15/2016).
`
`
`Declaration of DeForest McDuff, Ph.D.
`
`
`
`
`
`
`
`
`In the Inter Partes Review of U.S.
`Patent Nos. 6,858,650, 7,384,980,
`7,855,230, 7,985,772, 8,338,478
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1033 - Page 4
`
`
`
`million Americans are afflicted with OAB, including as many as 30% of men and
`
`40% of women.3
`
`9.
`
`There are various treatment options for OAB, including behavioral
`
`interventions, medications, Botox bladder injections, nerve stimulation, and in
`
`severe cases, surgery.4 Behavioral interventions include exercises to strengthen the
`
`pelvic floor muscle, maintaining a healthy weight, limiting fluid consumption, and
`
`wearing absorbent pads, among others.5 As of January 2016, nine branded
`
`prescription drugs are approved by the FDA to treat OAB, including: Botox
`
`(onabotulinumtoxina), Detrol (tolterodine tartrate), Detrol LA (tolterodine tartrate),
`
`Ditropan XL (oxybutynin chloride), Enablex (darifenacin), Gelnique (oxybutynin
`
`
`3
`Urology Care Foundation Website, What Is Overactive Bladder (OAB)?,
`
`http://www.urologyhealth.org/urologic-conditions/overactive-bladder-
`
`%28oab%29 (accessed 1/15/2016).
`
`4 Mayo Clinic Website, Overactive Bladder, Treatments and Drugs,
`
`http://www.mayoclinic.org/diseases-conditions/overactive-
`
`bladder/basics/treatment/con-20027632 (accessed 1/15/2016).
`
`5 Mayo Clinic Website, Overactive Bladder, Treatments and Drugs,
`
`http://www.mayoclinic.org/diseases-conditions/overactive-
`
`bladder/basics/treatment/con-20027632 (accessed 1/15/2016).
`
`
`Declaration of DeForest McDuff, Ph.D.
`
`
`
`
`
`
`
`
`In the Inter Partes Review of U.S.
`Patent Nos. 6,858,650, 7,384,980,
`7,855,230, 7,985,772, 8,338,478
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1033 - Page 5
`
`
`
`chloride), Myrbetriq (mirabegron), Oxytrol (oxybutynin), Toviaz (fesoterodine
`
`fumarate), and Vesicare (solifenacin succinate).6 At this time, available generic
`
`drugs include: oxybutynin chloride, oxybutynin chloride extended release,
`
`tolterodine tartrate, tolterodine tartrate extended release, trospium chloride, and
`
`trospium chloride extended release.7
`
`
`6
`NIH Website, DailyMed Label Search Results for Overactive Bladder,
`
`http://dailymed.nlm.nih.gov/dailymed/search.cfm?adv=1&query=34067-
`
`9%3A%28overactive+bladder%29&searchdb=all&labeltype=all&pagesize=
`
`200&audience=professional&page=1&sortby=alphabetically (accessed
`
`1/20/2016).
`
`7
`
`NIH Website, DailyMed Label Search Results for Overactive Bladder,
`
`http://dailymed.nlm.nih.gov/dailymed/search.cfm?adv=1&query=34067-
`
`9%3A%28overactive+bladder%29&searchdb=all&labeltype=all&pagesize=
`
`200&audience=professional&page=1&sortby=alphabetically (accessed
`
`1/20/2016).
`
`
`
`Flavoxate is also used to treat symptoms of OAB, though it is not indicated
`
`for the treatment of OAB. See:
`
`
`
`Declaration of DeForest McDuff, Ph.D.
`
`
`
`
`
`
`
`
`In the Inter Partes Review of U.S.
`Patent Nos. 6,858,650, 7,384,980,
`7,855,230, 7,985,772, 8,338,478
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1033 - Page 6
`
`
`
`
`
`Toviaz (fesoterodine)
`
`10. Toviaz is an extended-release tablet containing fesoterodine
`
`fumarate.8 Fesoterodine transforms in the body to release the active metabolite 5-
`
`hydroxymethyl tolterodine (“5-HMT”), which is a muscarinic receptor antagonist.9
`
`Muscarinic receptors play a role in contractions of urinary bladder smooth
`
`muscle.10 The effects of fesoterodine are the result of the inhibition of these
`
`receptors in the bladder.11 Fesoterodine is chemically similar to tolterodine, the
`
`active ingredient in Detrol and Detrol LA.12 Like fesoterodine, tolterodine
`
`
`
`Hesch, Kristen (2007), “Agents for Treatment of Overactive Bladder: A
`
`Therapeutic Class Review,” Proceedings (Baylor University Medical
`
`Center) 20(3): 307–314, at 307.
`
`Toviaz Label, 10/31/2008, at 1.
`
`Toviaz Label, 10/31/2008, at 1.
`
`Toviaz Label, 10/31/2008, at 1.
`
`Toviaz Label, 10/31/2008, at 1.
`
`Consumer Reports, “Evaluating Drugs Used to Treat: Overactive Bladder,”
`
`10/2013, at 5.
`
`Toviaz Label, 10/31/2008, at 1.
`
`Detrol LA Prescribing Information, 8/2012, at 8–9.
`
`8
`
`9
`
`10
`
`11
`
`12
`
`
`
`
`
`
`Declaration of DeForest McDuff, Ph.D.
`
`
`
`
`
`
`
`
`In the Inter Partes Review of U.S.
`Patent Nos. 6,858,650, 7,384,980,
`7,855,230, 7,985,772, 8,338,478
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1033 - Page 7
`
`
`
`transforms in the body to form the active metabolite 5-HMT and its therapeutic
`
`effects are the result of antimuscarinic activity.13
`
`11. The Food and Drug Administration (“FDA”) approved Toviaz for
`
`treatment of OAB in October 2008.14 Toviaz is available in 4 mg and 8 mg tablets,
`
`taken once per day.15 Toviaz is manufactured by Pfizer Inc. (“Pfizer”) and became
`
`available in the U.S. in March 2009.16
`
`
`13 Detrol LA Prescribing Information, 8/2012, at 8–9.
`
`14
`
`FDA Drug Details Website, Toviaz,
`
`https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseactio
`
`n=Search.DrugDetails (accessed 1/15/2016).
`
`
`
`FDA Approval Letter, NDA 22-030, 10/31/2008.
`
`15
`
`Consumer Reports, “Evaluating Drugs Used to Treat: Overactive Bladder,”
`
`10/2013, at 12.
`
`FDA Drug Details Website, Toviaz,
`
`https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseactio
`
`n=Search.DrugDetails (accessed 1/15/2016).
`
`Toviaz Label, 10/31/2008, at 14.
`
`
`
`
`
`16
`
`IMS Health Presentation, “DTC Investment in the Pharmaceutical Industry -
`
`Current Trends,” 4/2011, at 12.
`
`
`Declaration of DeForest McDuff, Ph.D.
`
`
`
`
`
`
`
`
`In the Inter Partes Review of U.S.
`Patent Nos. 6,858,650, 7,384,980,
`7,855,230, 7,985,772, 8,338,478
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1033 - Page 8
`
`
`
`
`
`Patents at issue
`
`12. U.S. Patent No. 6,858,650 (“the ’650 patent”), entitled “Stable Salts of
`
`Novel Derivatives of 3,3-Diphenylpropylamines,” was filed on November 15,
`
`2000 and issued on February 22, 2005.17 The ’650 patent lists Claus Meese as the
`
`inventor and Schwarz Pharma AG (currently known as UCB Pharma GmbH18) as
`
`the assignee.19 The abstract reads as follows:20
`
`The present invention concerns highly pure, crystalline, stable
`
`compounds of novel derivatives of 3,3-diphenylpropylamines in the
`
`form of their salts, a method for the manufacture and highly pure,
`
`stable intermediate products.
`
`
`17
`Stable Salts of Novel Derivatives of 3,3-Diphenylpropylamines, U.S. Patent
`
`No. 6,858,650 (filed 11/15/2000, issued 2/22/2005).
`
`18
`
`Bloomberg Website, Company Overview of UCB Pharma GmbH,
`
`http://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapid=
`
`882300 (accessed 1/19/2016).
`
`19
`
`Stable Salts of Novel Derivatives of 3,3-Diphenylpropylamines, U.S. Patent
`
`No. 6,858,650 (filed 11/15/2000, issued 2/22/2005).
`
`20
`
`Stable Salts of Novel Derivatives of 3,3-Diphenylpropylamines, U.S. Patent
`
`No. 6,858,650 (filed 11/15/2000, issued 2/22/2005).
`
`
`Declaration of DeForest McDuff, Ph.D.
`
`
`
`
`
`
`
`
`In the Inter Partes Review of U.S.
`Patent Nos. 6,858,650, 7,384,980,
`7,855,230, 7,985,772, 8,338,478
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1033 - Page 9
`
`
`
`The method
`
`is
`
`in particular characterized by
`
`regio- and
`
`chemoselectivity and high yield. Salts of phenolic monoesters of 3,3-
`
`diphenylpropylamines are provided, that are particularly well-suited
`
`for use in pharmaceutical formulations. Preferred compounds are R-
`
`(+)-2-(3-diisopropylamino-1-phenyl-propyl)-4-
`
`hydroxymethylphenylisobutyrate ester hydrogen fumarate and R-(+)-
`
`2-(3-diisopropylamino-1-phenylpropyl)-4-
`
`hydroxymethylphenylisobutyrate
`
`ester
`
`hydrochloride
`
`hydrate.
`
`Furthermore, stable, crystalline
`
`intermediate products
`
`that are
`
`essential for obtaining the abovementioned salts are provided. A
`
`preferred
`
`intermediate product
`
`is R-(−)-3-(3-diisopropylamino-
`
`phenyl-propyl)-4-hydroxy-benzoic acid methyl ester.
`
`13. U.S. Patent No. 7,384,980 (“the ’980 patent”), entitled “Derivatives of
`
`3,3-Diphenylpropylamines,” was filed on August 10, 2005 and issued on June 10,
`
`2008.21 The ’980 patent lists Claus Meese and Bengt Sparf as the inventors and
`
`
`21 Derivatives of 3,3-Diphenylpropylamines, U.S. Patent No. 7,384,980 (filed
`
`8/10/2005, issued 6/10/2008).
`
`
`Declaration of DeForest McDuff, Ph.D.
`
`
`
`
`
`
`
`
`In the Inter Partes Review of U.S.
`Patent Nos. 6,858,650, 7,384,980,
`7,855,230, 7,985,772, 8,338,478
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1033 - Page 10
`
`
`
`Schwarz Pharma AG (currently known as UCB Pharma GmbH22) as the assignee.23
`
`The abstract reads as follows:24
`
`The
`
`invention
`
`concerns
`
`novel
`
`derivatives
`
`of
`
`3,3-
`
`diphenylpropylamines, methods for their preparation, pharmaceutical
`
`compositions containing the novel compounds, and the use of the
`
`compounds for preparing drugs. More particularly, the invention
`
`relates to novel prodrugs of antimuscarinic agents with superior
`
`pharmacokinetic properties compared to existing drugs such as
`
`oxybutynin and
`
`tolterodine, methods
`
`for
`
`their preparation,
`
`pharmaceutical compositions containing them, a method of using said
`
`compounds and compositions
`
`for
`
`the
`
`treatment of urinary
`
`
`22
`Bloomberg Website, Company Overview of UCB Pharma GmbH,
`
`http://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapid=
`
`882300 (accessed 1/19/2016).
`
`23 Derivatives of 3,3-Diphenylpropylamines, U.S. Patent No. 7,384,980 (filed
`
`8/10/2005, issued 6/10/2008).
`
`24 Derivatives of 3,3-Diphenylpropylamines, U.S. Patent No. 7,384,980 (filed
`
`8/10/2005, issued 6/10/2008).
`
`
`Declaration of DeForest McDuff, Ph.D.
`
`
`
`
`
`
`
`
`In the Inter Partes Review of U.S.
`Patent Nos. 6,858,650, 7,384,980,
`7,855,230, 7,985,772, 8,338,478
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1033 - Page 11
`
`
`
`incontinence, gastrointestinal hyperactivity (irritable bowel syndrome)
`
`and other smooth muscle contractile conditions.
`
`14. U.S. Patent No. 7,855,230 (“the ’230 patent”), entitled “Derivatives of
`
`3,3-Diphenylpropylamines,” was filed on April 17, 2008 and issued on December
`
`21, 2010.25 The ’230 patent lists Claus Meese and Bengt Sparf as the inventors
`
`and UCB Pharma GmbH as the assignee.26 The abstract reads as follows:27
`
`The
`
`invention
`
`concerns
`
`novel
`
`derivatives
`
`of
`
`3,3-
`
`diphenylpropylamines, methods for their preparation, pharmaceutical
`
`compositions containing the novel compounds, and the use of the
`
`compounds for preparing drugs. More particularly, the invention
`
`relates to novel prodrugs of antimuscarinic agents with superior
`
`pharmacokinetic properties compared to existing drugs such as
`
`oxybutynin and
`
`tolterodine, methods
`
`for
`
`their preparation,
`
`
`25 Derivatives of 3,3-Diphenylpropylamines, U.S. Patent No. 7,855,230 (filed
`
`4/17/2008, issued 12/21/2010).
`
`26 Derivatives of 3,3-Diphenylpropylamines, U.S. Patent No. 7,855,230 (filed
`
`4/17/2008, issued 12/21/2010).
`
`27 Derivatives of 3,3-Diphenylpropylamines, U.S. Patent No. 7,855,230 (filed
`
`4/17/2008, issued 12/21/2010).
`
`
`Declaration of DeForest McDuff, Ph.D.
`
`
`
`
`
`
`
`
`In the Inter Partes Review of U.S.
`Patent Nos. 6,858,650, 7,384,980,
`7,855,230, 7,985,772, 8,338,478
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1033 - Page 12
`
`
`
`pharmaceutical compositions containing them, a method of using said
`
`compounds and compositions
`
`for
`
`the
`
`treatment of urinary
`
`incontinence, gastrointestinal hyperactivity (irritable bowel syndrome)
`
`and other smooth muscle contractile conditions.
`
`15. U.S. Patent No. 7,985,772 (“the ’772 patent”), entitled “Derivatives of
`
`3,3-Diphenylpropylamines,” was filed on June 14, 2010 and issued on July 26,
`
`2011.28 The ’772 patent lists Claus Meese and Bengt Sparf as the inventors and
`
`UCB Pharma GmbH as the assignee.29 The abstract reads as follows:30
`
`The
`
`invention
`
`concerns
`
`novel
`
`derivatives
`
`of
`
`3,3-
`
`diphenylpropylamines, methods for their preparation, pharmaceutical
`
`compositions containing the novel compounds, and the use of the
`
`compounds for preparing drugs. More particularly, the invention
`
`relates to novel prodrugs of antimuscarinic agents with superior
`
`
`28 Derivatives of 3,3-Diphenylpropylamines, U.S. Patent No. 7,985,772 (filed
`
`6/14/2010, issued 7/26/2011).
`
`29 Derivatives of 3,3-Diphenylpropylamines, U.S. Patent No. 7,985,772 (filed
`
`6/14/2010, issued 7/26/2011).
`
`30 Derivatives of 3,3-Diphenylpropylamines, U.S. Patent No. 7,985,772 (filed
`
`6/14/2010, issued 7/26/2011).
`
`
`Declaration of DeForest McDuff, Ph.D.
`
`
`
`
`
`
`
`
`In the Inter Partes Review of U.S.
`Patent Nos. 6,858,650, 7,384,980,
`7,855,230, 7,985,772, 8,338,478
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1033 - Page 13
`
`
`
`pharmacokinetic properties compared to existing drugs such as
`
`oxybutynin and
`
`tolterodine, methods
`
`for
`
`their preparation,
`
`pharmaceutical compositions containing them, a method of using said
`
`compounds and compositions
`
`for
`
`the
`
`treatment of urinary
`
`incontinence, gastrointestinal hyperactivity (irritable bowel syndrome)
`
`and other smooth muscle contractile conditions.
`
`16. U.S. Patent No. 8,338,478 (“the ’478 patent”), entitled “Derivatives of
`
`3,3-Diphenylpropylamines,” was filed on June 15, 2011 and issued on December
`
`25, 2012.31 The ’478 patent lists Claus Meese and Bengt Sparf as the inventors
`
`and UCB Pharma GmbH as the assignee.32 The abstract reads as follows:33
`
`The
`
`invention concerns novel derivatives of 3,3-diphenyl-
`
`propylamines, methods
`
`for
`
`their preparation, pharmaceutical
`
`compositions containing the novel compounds, and the use of the
`
`
`31 Derivatives of 3,3-Diphenylpropylamines, U.S. Patent No. 8,338,478 (filed
`
`6/15/2011, issued 12/25/2012).
`
`32 Derivatives of 3,3-Diphenylpropylamines, U.S. Patent No. 8,338,478 (filed
`
`6/15/2011, issued 12/25/2012).
`
`33 Derivatives of 3,3-Diphenylpropylamines, U.S. Patent No. 8,338,478 (filed
`
`6/15/2011, issued 12/25/2012).
`
`
`Declaration of DeForest McDuff, Ph.D.
`
`
`
`
`
`
`
`
`In the Inter Partes Review of U.S.
`Patent Nos. 6,858,650, 7,384,980,
`7,855,230, 7,985,772, 8,338,478
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1033 - Page 14
`
`
`
`compounds for preparing drugs. More particularly, the invention
`
`relates to novel prodrugs of antimuscarinic agents with superior
`
`pharmacokinetic properties compared to existing drugs such as
`
`oxybutynin and
`
`tolterodine, methods
`
`for
`
`their preparation,
`
`pharmaceutical compositions containing them, a method of using said
`
`compounds and compositions
`
`for
`
`the
`
`treatment of urinary
`
`incontinence, gastrointestinal hyperactivity (irritable bowel syndrome)
`
`and other smooth muscle contractile conditions.
`
`17. UCB Pharma GmbH granted Pfizer an exclusive, worldwide license to
`
`the above patents at issue.34 I understand that the patents at issue, among others,
`
`are represented to cover Pfizer’s Toviaz drug.35
`
`
`34
`Pfizer Inc., Form 10-K, 2015, at Exhibit 13, p. 107.
`
`35
`
`FDA Website, Orange Book, Toviaz 4MG (NDA 022030),
`
`https://www.accessdata.fda.gov/scripts/cder/ob/docs/patexclnew.cfm?Appl_
`
`No=022030&Product_No=001&table1=OB_Rx (accessed 1/13/2016).
`
`
`
`FDA Website, Orange Book, Toviaz 8MG (NDA 022030),
`
`https://www.accessdata.fda.gov/scripts/cder/ob/docs/patexclnew.cfm?Appl_
`
`No=022030&Product_No=002&table1=OB_Rx (accessed 1/13/2016).
`
`
`Declaration of DeForest McDuff, Ph.D.
`
`
`
`
`
`
`
`
`In the Inter Partes Review of U.S.
`Patent Nos. 6,858,650, 7,384,980,
`7,855,230, 7,985,772, 8,338,478
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1033 - Page 15
`
`
`
`III. Analysis of Commercial Success
`
` Economic relevance of commercial success
`
`18. Commercial success is a secondary consideration that a patent owner
`
`may use to argue that its patent is not obvious based on the alleged commercial
`
`success of an invention embodying that patent. I understand that commercial
`
`success may be relevant to the determination of a patent’s obviousness since the
`
`law presumes that an idea would have been brought to market sooner in response
`
`to market forces had it been obvious to persons skilled in the art. I further
`
`understand that evidence of commercial success is only relevant if there is a nexus
`
`between the alleged commercial success and the patentable features of the asserted
`
`claims. In other words, the patent owner must show that the commercial success is
`
`attributable to the novel parts of a patent claim, and not on factors that are
`
`unrelated or were already known.
`
`19. From an economic perspective, commercial success presumes that if
`
`an idea were obvious to market participants, then others would have brought that
`
`idea to market sooner had there been economic incentives to do so. A finding of
`
`commercial success can, in some circumstances, support the notion that a patent
`
`was not obvious to those skilled in the art if those incentives for development
`
`existed. Accordingly, analysis of commercial success frequently includes
`
`
`Declaration of DeForest McDuff, Ph.D.
`
`
`
`
`
`
`
`
`In the Inter Partes Review of U.S.
`Patent Nos. 6,858,650, 7,384,980,
`7,855,230, 7,985,772, 8,338,478
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1033 - Page 16
`
`
`
`evaluation of sales, profits, market shares, prices, and other metrics to draw
`
`inferences on potential economic incentives for development.
`
`
`
`Toviaz’s market share, pricing, and sales have been relatively low
`
`20. Toviaz’s commercial performance in the OAB market does not
`
`demonstrate commercial success. To the contrary, several factors indicate that
`
`Toviaz’s commercial performance has been relatively low: (1) Toviaz’s market
`
`share has been low, despite substantial marketing and promotion efforts, (2) Toviaz
`
`has not commanded a price premium, and instead has been heavily discounted, (3)
`
`Toviaz sales have been low compared to other OAB drugs, despite Pfizer’s express
`
`efforts to switch Detrol patients to Toviaz, and (4) Toviaz sales have been low
`
`compared to average drugs.
`
`21. First, Toviaz’s market share has been relatively low. Toviaz’s share
`
`of total U.S. prescriptions in the OAB market was 0.6% in 2009, 2.6% in 2010,
`
`3.9% in 2011, 4.5% in 2012, 5.4% at its peak in 2013, and 5.3% in 2014. See
`
`Exhibit 1037. Toviaz’s share of total U.S. revenue in the OAB market was 0.7% in
`
`2009, 3.9% in 2010, 7.7% in 2011, 9.1% in 2012, 7.2% in 2013, and 7.4% in 2014.
`
`See Exhibit 1038. Prescription shares are more representative of share of use and
`
`are thus more informative here, since revenue shares are impacted by low-priced
`
`generic alternatives and reflect higher branded prices rather than share of use.
`
`
`Declaration of DeForest McDuff, Ph.D.
`
`
`
`
`
`
`
`
`In the Inter Partes Review of U.S.
`Patent Nos. 6,858,650, 7,384,980,
`7,855,230, 7,985,772, 8,338,478
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1033 - Page 17
`
`
`
`Nevertheless, neither of these market shares demonstrate Toviaz filling a
`
`substantial market gap or indicate commercial success of Toviaz.
`
`22. Second, Pfizer has not charged premium prices for Toviaz, despite it
`
`being a branded drug, and in fact, Toviaz is among the least expensive branded
`
`OABs available. For example, Consumer Reports reported that, as of June 2010,
`
`Toviaz was the third least expensive branded OAB drug out of eleven branded
`
`drugs.36 In October 2013, Consumer Reports reported that Toviaz was the second
`
`least expensive branded OAB drug out of ten branded drugs.37
`
`23. Evidence indicates that Pfizer provides substantial price discounts on
`
`Toviaz. For example, U.S. patients without prescription medication insurance
`
`coverage are eligible to receive Toviaz at a discount of 36% to 75%.38 As another
`
`
`36
`Consumer Reports, “Evaluating Drugs Used to Treat: Overactive Bladder,”
`
`6/2010, at 11.
`
`37
`
`Consumer Reports, “Evaluating Drugs Used to Treat: Overactive Bladder,”
`
`10/2013, at 12–13.
`
`38
`
`Pfizer Pathways Website, Search for Services, Toviaz,
`
`http://www.pfizerrxpathways.com/en/?step=1 (accessed 1/20/2016).
`
`
`
`Declaration of DeForest McDuff, Ph.D.
`
`
`
`
`
`
`
`
`In the Inter Partes Review of U.S.
`Patent Nos. 6,858,650, 7,384,980,
`7,855,230, 7,985,772, 8,338,478
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1033 - Page 18
`
`
`
`example, Pfizer offers a discount of $45 per Toviaz prescription, plus one month of
`
`Toviaz free.39 From an economic perspective, if Toviaz was differentiated
`
`compared to other OAB drugs as a result of its patented features, Pfizer should
`
`have been able to charge a premium price compared to competing products. The
`
`fact that Toviaz was competing on price is not indicative of commercial success.
`
`24. Third, Toviaz sales have been low compared to other OAB drugs.
`
`From an economic perspective, sales by themselves do not demonstrate
`
`commercial success; rather, sales must be put into proper context, such as
`
`comparisons with other OAB drugs.40 Indeed, a number of other OAB drugs have
`
`
`
`Pfizer Pathways Website, Services for Uninsured and Insured Patients,
`
`http://www.pfizerrxpathways.com/en/see-how-we-
`
`help?program_id=program-18#tabs-0-middle-1 (accessed 1/20/2016).
`
`39
`
`Rx Pharmacy Coupons Website, Toviaz Prescription Discounts,
`
`http://www.rxpharmacycoupons.com/toviaz-manufacturer-coupon-2.html
`
`(accessed 1/20/2016).
`
`40
`
`See, for example: U.S. Patent and Trademark Office, Manual of Patent
`
`Examining Procedure, Eighth Edition, Revision: 7/2010, 716.03(b) IV., at
`
`700-300 (“Gross sales figures do not show commercial success absent
`
`evidence as to market share, Cable Electric Products, Inc. v. Genmark, Inc.,
`
`
`
`Declaration of DeForest McDuff, Ph.D.
`
`
`
`
`
`
`
`
`In the Inter Partes Review of U.S.
`Patent Nos. 6,858,650, 7,384,980,
`7,855,230, 7,985,772, 8,338,478
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1033 - Page 19
`
`
`
`outperformed Toviaz. For example, in 2012, Toviaz had approximately 800,000
`
`total prescriptions, far below market leaders including generic Ditropan at 4.1
`
`million prescriptions, Vesicare at 3.9 million prescriptions, generic Ditropan XL at
`
`3.9 million prescriptions, Detrol LA at 2.7 million prescriptions, and Enablex at 1.3
`
`million prescriptions. See Exhibit 1037. In 2014, Toviaz’s 973,800 total
`
`prescriptions were well below the total prescriptions earned by generic Ditropan
`
`XL with 4.8 million, generic Ditropan with 4.4 million, Vesicare with 3.7 million,
`
`generic Detrol LA with 1.6 million, and Myrbetiq with 1.1 million. See Exhibit
`
`1037. In 2014, Toviaz U.S. revenue ranked only fourth among OAB drugs, with
`
`approximately $133.0 million in revenues, well below the $822.9 million earned
`
`by Vesicare, $237.2 million earned by Myrbetriq, as well as the $262.7 million
`
`earned by the generic version of Detrol LA, despite few competing branded drugs
`
`on the market. See Exhibit 1038.
`
`25. Similarly, Toviaz prescriptions and revenue in the first six years after
`
`launch were significantly less than other OAB branded drugs normalized for the
`
`
`770 F.2d 1015, 226 USPQ 881 (Fed. Cir. 1985), or as to the time period
`
`during which the product was sold, or as to what sales would normally be
`
`expected in the market, Ex parte Standish, 10 USPQ2d 1454 (Bd. Pat. App.
`
`& Inter. 1988).”).
`
`
`Declaration of DeForest McDuff, Ph.D.
`
`
`
`
`
`
`
`
`In the Inter Partes Review of U.S.
`Patent Nos. 6,858,650, 7,384,980,
`7,855,230, 7,985,772, 8,338,478
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1033 - Page 20
`
`
`
`same timeframe. In the first year after launch, Toviaz had approximately 111,000
`
`total prescriptions, compared to 2.4 million prescriptions for Detrol LA, 459,000
`
`for Vesicare, 385,000 prescriptions for Enablex, and 331,000 prescriptions for
`
`Oxytrol. See Exhibit 1040. Over the first six years of sales, Toviaz prescriptions
`
`totaled approximately 4.0 million, well below 33.7 million for Detrol LA, 12.8
`
`million for Vesicare, and 8.0 million for Enablex. See Exhibit 1040. Similarly,
`
`Toviaz’s total revenue of $527.7 million for the first six years of sales falls below
`
`$3.2 billion for Detrol LA, $902.4 million for Vesicare, and $884.6 million for
`
`Enablex over the same timeframe. See Exhibit 1041.
`
`26. Toviaz has also had lower sales and use than Myrbetriq (mirabegron),
`
`a drug that entered the OAB market three years after Toviaz.41 Just two years after
`
`its launch, Myrbetriq surpassed Toviaz’s market share, both in terms of total U.S.
`
`prescriptions and total U.S. revenue. See Exhibits 1037 and 1038. In its first three
`
`years of sales, Myrbetriq earned 1.6 million prescriptions and $342.1 million in
`
`
`41 Astellas Pharma US Press Release, “MYRBETRIQ™ (Mirabegron),
`
`Overactive Bladder Treatment from Astellas, Now Available Through U.S.
`
`Pharmacies,” 10/22/2012,
`
`https://www.astellas.us/docs/us/Myrbetriq_Product_Availability_Press_Rele
`
`ase_FINAL.pdf?v=1.
`
`
`Declaration of DeForest McDuff, Ph.D.
`
`
`
`
`
`
`
`
`In the Inter Partes Review of U.S.
`Patent Nos. 6,858,650, 7,384,980,
`7,855,230, 7,985,772, 8,338,478
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1033 - Page 21
`
`
`
`revenue, exceeding the 1.3 million prescriptions and $159.5 million in revenue
`
`earned by Toviaz during its first three years of sales. See Exhibits 1040 and 1041.
`
`27. Fourth, Toviaz sales have fallen short compared to average drug
`
`sales, which tend to be close to break-even in terms of economic profitability,
`
`taking into account all costs and profits associated with development and
`
`commer